Eurosurv. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohor

[tetano]

• Irina Kislaya[SUP]1,2[/SUP] , Ausenda Machado[SUP]1,2[/SUP] , Sarah Magalhães[SUP]3[/SUP] , Ana Paula Rodrigues[SUP]1[/SUP] , Rafael Franco[SUP]3[/SUP] , Pedro Pinto Leite[SUP]4[/SUP] , Carlos Matias Dias[SUP]1,2[/SUP] , Baltazar Nunes[SUP]1,2[/SUP]

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.37.2200697#html_fulltext